<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03683498</url>
  </required_header>
  <id_info>
    <org_study_id>GVHD-TReG</org_study_id>
    <nct_id>NCT03683498</nct_id>
  </id_info>
  <brief_title>Donor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-host-Disease</brief_title>
  <acronym>GVHD-TReG</acronym>
  <official_title>A Phase I Trial of Donor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-Host-Disease in Patients Who do Not Obtain Complete Remission With Ruxolitinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase I Trial of Donor Regulatory T-cells for Steroid-Refractory Chronic&#xD;
      Graft-versus-Host-Disease in patients who do not obtain complete remission with ruxolitinib&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study design is based on a phase I trial in Spanish.&#xD;
&#xD;
      A number of 16 patients will be included to assess the safety and maximum tolerated&#xD;
      dose-level of donor regulatory enriched T cell (Treg) in steroid-refractory chronic graft&#xD;
      versus host disease (cGVHD) patients who did not obtain complete remission under treatment&#xD;
      with ruxolitinib.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 25, 2018</start_date>
  <completion_date type="Anticipated">March 22, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 22, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Initial enrollment will be at Dose-level A. Subsequent cohorts will be dose escalated.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity and maximum tolerated dose</measure>
    <time_frame>Up 12 weeks after infusion</time_frame>
    <description>To determine the maximum tolerated dose (MTD) and toxicity of Treg-enriched infusion among patients receiving ruxolitinib.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantification of targeted cells of manufacturing Treg-enriched product meeting the targeted cell dose-level.</measure>
    <time_frame>Before 24 hours to infusion up infusion day</time_frame>
    <description>Percentage of cells viability, negative gram stain/endotoxin, percentage of CD4+CD25+ cells and CD4+CD25+CD127- Treg in order to consider for the infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response of Treg-enriched infusion</measure>
    <time_frame>Up 12 weeks after Treg infusion</time_frame>
    <description>Each participant should be assigned one of the following categories: 1) complete cGVHD response per NIH criteria, 2) partial cGVHD response per NIH criteria, 3) non-response (includes stable disease) per NIH criteria, 4) progressive cGVHD per NIH criteria, 5) malignant disease relapse, or 6) unknown (not assessable, insufficient data).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunologic effects through phenotypical evaluation</measure>
    <time_frame>Up 12 weeks after Treg infusion</time_frame>
    <description>Phenotypical evaluation of T cell populations (CD4, CD8, Treg), B and NK cells nuclear cells of Treg-enriched infusion among patients receiving ruxolitinib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunologic effects through immune globulins.</measure>
    <time_frame>Up 12 weeks after Treg infusion</time_frame>
    <description>Quantitative immune globulins of Treg-enriched infusion among patients receiving ruxolitinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunologic effects through plasma banking</measure>
    <time_frame>Up 12 weeks after Treg infusion</time_frame>
    <description>Plasma banking of Treg-enriched infusion among patients receiving ruxolitinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunologic effects through additional mononuclear cells.</measure>
    <time_frame>Up 12 weeks after Treg infusion</time_frame>
    <description>Storage of additional mononuclear cells of Treg-enriched infusion among patients receiving ruxolitinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival after one year of Treg infusion</measure>
    <time_frame>1 year after Treg infusion</time_frame>
    <description>Number of patients alive after one year of Treg infusion</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Chronic Graft vs Host Disease</condition>
  <arm_group>
    <arm_group_label>Regulatory T-cell enriched infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation sequential cohorts Regulatory T-cell enriched infusion (Cells/kg) will be administered. The cohorts will be dose escalated per the schema below:&#xD;
Dose-level A: 0.5 x 10ˆ6 Cells/kg Dose-level B: 1 x 10ˆ6 cell/kg Dose-level C: 2 x 10ˆ6 cell/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Regulatory T-cell enriched infusion</intervention_name>
    <description>Enrichment of CD25hi regulatory T cells from CD8 and/or CD19 pre-depleted leukapheresis products.</description>
    <arm_group_label>Regulatory T-cell enriched infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Recipient of allogeneic hematopoietic stem cell transplantation.&#xD;
&#xD;
          -  Participants must have steroid-refractory cGVHD and had obtained a partial response&#xD;
             after at least 4 weeks of treatment with ruxolitinib.&#xD;
&#xD;
          -  Steroid-refractory cGVHD is defined as having persistent signs and symptoms of cGVHD&#xD;
             (Appendix D) despite the use of prednisone at ≥0.25 mg/kg/day (or 0.5 mg/kg every&#xD;
             other day) for at least 4 weeks (or equivalent dosing of alternate glucocorticoids)&#xD;
             without complete resolution of signs and symptoms.&#xD;
&#xD;
          -  Stable dose of glucocorticoids for 4 weeks prior to enrolment&#xD;
&#xD;
          -  No addition or subtraction of other immunosuppressive medications (e.g.,&#xD;
             calcineurin-inhibitors, sirolimus, mycophenolate-mofetil) for 4weeks prior to&#xD;
             enrolment. The dose of immunosuppressive medicines may be adjusted based on the&#xD;
             therapeutic range of that drug&#xD;
&#xD;
          -  No age limit. In the case of children participating in the study, the informed consent&#xD;
             will be signed by a parents or legal guardians&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2&#xD;
&#xD;
          -  Participants must have adequate organ function&#xD;
&#xD;
          -  Women of child-bearing potential and men must agree to use adequate contraception&#xD;
             (hormonal or barrier method of birth control; abstinence) prior to study entry and for&#xD;
             the duration of study participation. Should a woman become pregnant or suspect she is&#xD;
             pregnant while participating in this study, she should inform her treating physician&#xD;
             immediately&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ongoing prednisone requirement &gt;1 mg/kg/day (or equivalent).&#xD;
&#xD;
          -  Concurrent use of calcineurin-inhibitor plus sirolimus (either agent alone is&#xD;
             acceptable).&#xD;
&#xD;
          -  History of thrombotic microangiopathy, hemolytic-uremic syndrome or thrombotic&#xD;
             thrombocytopenic purpura.&#xD;
&#xD;
          -  New immunosuppressive medication in the 4 weeks prior.&#xD;
&#xD;
          -  Extra-corporeal Photopheresis or rituximab therapy in the 4 weeks prior.&#xD;
&#xD;
          -  Post-transplant exposure to T-cell or Interleukin-2 targeted medication (e.g.&#xD;
             alemtuzumab, basiliximab, denileukin diftitox) within 100 days prior.&#xD;
&#xD;
          -  Donor lymphocyte infusion within 100 days prior.&#xD;
&#xD;
          -  Active malignant relapse.&#xD;
&#xD;
          -  Active uncontrolled infection.&#xD;
&#xD;
          -  Organ transplant (allograft) recipient.&#xD;
&#xD;
          -  HIV-positive individuals on combination antiretroviral therapy are ineligible because&#xD;
             of the potential for pharmacokinetic interactions with the agents used after&#xD;
             allogeneic hematopoietic stem cell transplant (HSCT). In addition, these individuals&#xD;
             are at increased risk of lethal infections. Appropriate studies will be undertaken in&#xD;
             participants receiving combination antiretroviral therapy when indicated.&#xD;
&#xD;
          -  Individuals with active uncontrolled hepatitis B or C are ineligible as they are at&#xD;
             high risk of lethal treatment-related hepatotoxicity after hematopoietic stem cell&#xD;
             transplant (HSCT).&#xD;
&#xD;
          -  Other investigational drugs within 4 weeks prior to enrolment, unless cleared by the&#xD;
             Principal Investigator.&#xD;
&#xD;
          -  Pregnant women are excluded from this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José Antonio Pérez-Simón, M.D. Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Hematology, Hospital Universitario Virgen del Rocío, Sevilla.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <state>Seville</state>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 18, 2018</study_first_submitted>
  <study_first_submitted_qc>September 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2018</study_first_posted>
  <last_update_submitted>April 12, 2021</last_update_submitted>
  <last_update_submitted_qc>April 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ruxolitinib</keyword>
  <keyword>T cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

